Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC 50 for a proof-of-principle study
| Autor: | Emmanuel Bey, Chris J. van Koppen, Matthias W. Laschke, Mohamed Salah, Carsten Börger, Martin Frotscher, Ahmed S. Abdelsamie, Lorenz Siebenbürger, Michael D. Menger |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.drug_class Cell Estrogen receptor Estrone Pharmacology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Drug Discovery medicine IC50 chemistry.chemical_classification Pregnane X receptor biology Chemistry Organic Chemistry General Medicine 030104 developmental biology Enzyme medicine.anatomical_structure Estrogen Enzyme inhibitor 030220 oncology & carcinogenesis biology.protein hormones hormone substitutes and hormone antagonists |
| Zdroj: | European Journal of Medicinal Chemistry. 127:944-957 |
| ISSN: | 0223-5234 |
| Popis: | Current endocrine therapeutics for the estrogen-dependent disease endometriosis often lead to considerable side-effects as they act by reducing estrogen action systemically. A more recent approach takes advantage of the fact that the weak estrogen estrone (E1) which is abundant in the plasma, is activated in the target cell to the highly estrogenic estradiol (E2) by 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). 17β-HSD1 is overexpressed in endometriosis and thus a promising target for the treatment of this disease, with the prospect of less target-associated side-effects. Potent inhibitors from the class of bicyclic substituted hydroxyphenylmethanones with sulfonamide moiety recently described by us suffered from high molecular weight and low selectivity over 17βHSD2, the physiological adversary of 17β-HSD1. We describe the structural optimizations leading to the discovery of (5-(3,5-dichloro-4-methoxyphenyl)thiophen-2-yl)(2,6-difluoro-3-hydroxyphenyl)methanone 20, which displayed a sub-nanomolar IC50 towards 17β-HSD1 as well as high selectivity over the type 2 enzyme, the estrogen receptors α and β and a range of hepatic CYP enzymes. The compound did neither show cellular toxicity, nor PXR activation nor mutagenicity in the AMES II assay. Additional favourable pharmacokinetic properties (rat) make 20 a suitable candidate for proof-of-principle studies using xenotransplanted immunodeficient rats. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect